Description
Limosilactobacillus reuteri DSM 17938 is a daughter strain of the original ATCC 55730 isolate, engineered through plasmid curing to remove non-essential antibiotic resistance plasmids while retaining the full probiotic phenotype. It is the most clinically validated strain in the infant probiotic drop category globally.
Supplied as a freeze-dried powder or oil-suspension premix with viability between 50 and 300 billion CFU per gram at release. The strain demonstrates exceptional acid and bile tolerance and the capacity to colonize the infant gut transiently.
Off-white to pale beige free-flowing powder, or amber oil suspension in food-grade triglyceride carrier. Particle size suitable for infant drops, chewable tablets, oral suspensions, and capsule applications.
We supply food-grade and pharmaceutical-grade Limosilactobacillus reuteri DSM 17938 commercial-equivalent strain from manufacturers in China holding ISO 22000, FSSC 22000, GMP, Halal, Kosher, and other certifications relevant to probiotic strain production.
Common market grades include 50, 100, and 300 billion CFU per gram freeze-dried powders, oil-suspension premixes ready for infant drop filling, chewable tablet blends, and capsule grades. Bulk and reduced-MOQ shipments with batch-level COA covering viable count, strain identity, moisture, heavy metals, and pathogen panel.
Introduction
The DSM 17938 strain was developed by BioGaia AB by curing the two non-essential plasmids carrying resistance genes from the parent ATCC 55730 isolate, resulting in an antibiotic-resistance-gene-free probiotic strain otherwise phenotypically identical to its parent. The strain is the basis of the BioGaia Protectis brand and is the most widely studied infant probiotic in the global literature.
Industrial production uses anaerobic batch fermentation in MRS-based proprietary media supplemented with glycerol, followed by biomass harvest, cryoprotectant blending with trehalose, and lyophilization. Oil-suspension premixes are produced by dispersing the dried powder in food-grade sunflower oil or medium-chain triglyceride carrier under nitrogen blanket to maintain viability over an 18 to 24 month shelf life.
Regulatory status includes GRAS notification GRN 254 with FDA, Qualified Presumption of Safety listing in the European Union, and inclusion in pediatric clinical guidelines for infant colic management in many countries.
Clinical evidence covers over 200 published trials including double-blind placebo-controlled studies supporting use in infant colic, regurgitation, functional constipation in children, and Helicobacter pylori eradication adjunct therapy in adults.
Where it is used
- Infant probiotic drops for colic, regurgitation, and functional gastrointestinal disorders
- Pediatric probiotic suspensions and sachets
- Adult chewable tablets for oral and digestive health
- Maternal and lactation support supplements
- Preterm infant supportive care formulations
- Functional constipation in children
- Multi-strain pediatric probiotic stacks
- Capsules for adult Helicobacter pylori adjunct support
- Gum and lozenge oral health applications
Technical data
| Item | Specification |
|---|---|
| Appearance | Off-white to pale beige powder, or amber oil suspension |
| Viable cell count | ≥ 100 billion CFU/g (50B, 100B, 300B grades) |
| Strain identity | Confirmed by 16S rRNA sequencing and PFGE (DSM 17938 pattern) |
| Antibiotic resistance plasmids | Absent (confirmed by PCR) |
| Moisture (loss on drying) | ≤ 5.0% |
| Particle size | ≥ 95% through 80 mesh (powder) |
| Heavy metals (as Pb) | ≤ 1 mg/kg |
| Arsenic | ≤ 0.5 mg/kg |
| Salmonella | Absent in 25 g |
| E. coli | Absent in 10 g |
| Yeast and mold | ≤ 50 CFU/g |
| Shelf life | 18 to 24 months from manufacture under recommended storage |
| Storage | −18 °C sealed; 2 to 8 °C after opening |
Ready to discuss business?
Send us your spec and requirement. We will respond with availability and pricing within 24 hours.